Cancer Specialists Wield Breakthrough Courses in Fight against Mesothelioma, though Prognosis Remains Grim
Oncologists and other cancer doctors determine what kind of treatment to go with to their patient. The options are endless. There are no universal treatment option for pleural mesothelioma cancer victims. Mesotheliomas lack of agreed-upon treatment is due to low a treatment success rate, rareness, a high mortality rate and a small number of studies providing meaningful stats.
While prospects for patients with mesothelioma have been bleak, doctors have been making progress. Treatments for cancer are traditionally surgery (taking out the tumor and surrounding tissue), radiation (killing the cancerous cells with radiation), and chemotherapy (poisoning the cancerous cells.) All three methods have problems. Patients with mesothelioma have not responded well to traditional radiation therapy. In hopes to lessen damage to healthy tissue, researches are studying ways to aim radiation right at the tumor.
Surgery takes out the mesothelial cancerous tissue around the tumor. It is a grueling surgery with unknown benefits to patients. Most chemotherapy medication that work on other cancers typically do not work on mesothelioma, and combinations of chemotherapy agents have been tried, but without much success. Similar to radiation, focus in research is focusing on treating the physical location of the tumor with emphasis on the pleural cavity.
The high-mortality rate for mesothelioma patients means cutting-edge techniques for cancer are tried out. These include biologic therapy such as the agent interleukin 2 and anti-angiogenesis drugs such as thalidomide. The new drug pemetrexed (brand name Alimta) has shown good results in extending life with mesotheliomas..
Considered by oncologists is where the tumor is located, what stage the mesothelioma is in, and the age and health of the patient. Theres also photodynamic therapy and gene therapy ” two far-out new ways of attacking cancer. Patients afflicted with mesothelioma are benefitting in these clinical trials.











